Brand-Generic Pay-For-Delay Deals May Become Extinct, FTC Finds
Executive Summary
Only one of 232 brand-generic patent suit settlements in the US during FY 2016 contained a side deal or commitment not to market an authorized generic.
You may also be interested in...
FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments
Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.
FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments
Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.
Bills To Speed Generic Entry Once Again Clear Senate Judiciary Committee
Legislation to prevent pay-for-delay deals, product hopping and sham citizen petitions, and to require the FTC to study the role of pharmacy benefit managers in the drug supply chain get unanimous committee vote. They may have a good shot at passage given recent actions by President Biden and the FTC, and bipartisan interest in drug pricing.